Methods of treating conditions related to the s1p1 receptor
AssigneeArena Pharmaceuticals, Inc.
InventorsGurpreet AHLUWALIA, Maple M FUNG, Andrew Christopher Wesley SELFRIDGE
Life of this patent
Estimating the term…
Abstract
Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed. Additionally, described here are new methods of treating moderate to severe atopic dermatitis.
Claims36
A method of treating moderate to severe atopic dermatitis comprising:
- administering etrasimod, or a pharmaceutically acceptable salt thereof, to a patient in need thereof;
- identifying a threshold absolute lymphocyte count (ALC) in the patient;
- ceasing administration of the etrasimod, or a pharmaceutically acceptable salt thereof, for an interruption period of time;
- and
- after ceasing administration for the interruption period of time, continuing to administer the etrasimod, or a pharmaceutically acceptable salt thereof, for a continuation period of time;
- wherein the patient in need thereof experiences an improvement in moderate to severe atopic dermatitis.
(canceled)
(canceled)
(canceled)
10-13. (canceled)
(canceled)
(canceled)
(canceled)
A method of treating moderate to severe atopic dermatitis comprising:
- administering etrasimod, or a pharmaceutically acceptable salt thereof, to a patient in need thereof;
- monitoring the patient for one or more infections after administration of the etrasimod or a pharmaceutically acceptable salt thereof;
- ceasing administration of the etrasimod, or a pharmaceutically acceptable salt thereof, for an interruption period of time;
- after ceasing administration for the interruption period of time, continuing to administer the etrasimod, or a pharmaceutically acceptable salt thereof, for a continuation period of time;
- wherein the method is therapeutically effective to treat moderate to severe atopic dermatitis.
(canceled)
(canceled)
25-28. (canceled)
(canceled)
35-38. (canceled)
A method of treating or ameliorating at least one symptom or indication of atopic dermatitis in an individual in need thereof, comprising:
- administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof, wherein the Compound 1 or pharmaceutically acceptable salt thereof is administered an amount equivalent to more than 2 mg.
40-42. (canceled)
44-47. (canceled)
The method of claim 45, wherein the patient is diagnosed with moderate atopic dermatitis and has a vIGA score of 3 or the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.
(canceled)
(canceled)
Dependencies are inferred from the claim text.